(VIANEWS) – Shares of Novavax (NASDAQ: NVAX) jumped by a staggering 21.65% in 10 sessions from $6.07 at 2023-03-22, to $7.38 at 10:23 EST on Wednesday, following the last session’s downward trend. NASDAQ is sliding 0.52% to $12,126.33, after two sequential sessions in a row of losses.
Novavax’s last close was $7.34, 90.55% under its 52-week high of $77.65.
About Novavax
Novavax, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of vaccines to prevent serious infectious diseases and address health needs. The company's vaccine candidates include NVX-CoV2373, a coronavirus vaccine candidate that is in two Phase III trials, one Phase IIb trial, and one Phase I/II trial; NanoFlu, a nanoparticle seasonal quadrivalent influenza vaccine candidate that is in Phase 3 clinical trial; and ResVax, a respiratory syncytial virus (RSV) fusion (F) protein nanoparticle vaccine candidate. It is also developing RSV F vaccine that is in Phase II clinical trial for older adults (60 years and older), as well as that is in Phase I clinical trial for pediatrics. It has a collaboration agreement with Takeda Pharmaceutical Company Limited for the development, manufacturing, and commercialization of NVX-CoV2373, a COVID-19 vaccine candidate. Novavax, Inc. was incorporated in 1987 and is headquartered in Gaithersburg, Maryland.
Earnings Per Share
As for profitability, Novavax has a trailing twelve months EPS of $-7.27.
Volume
Today’s last reported volume for Novavax is 572963 which is 91.18% below its average volume of 6391630.
Yearly Top and Bottom Value
Novavax’s stock is valued at $7.38 at 10:23 EST, way below its 52-week high of $77.65 and way higher than its 52-week low of $5.61.
More news about Novavax (NVAX).
